Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Non-Current Debt (2017 - 2025)

Historic Non-Current Debt for Ani Pharmaceuticals (ANIP) over the last 9 years, with Q3 2025 value amounting to $297.7 million.

  • Ani Pharmaceuticals' Non-Current Debt fell 487.06% to $297.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.7 million, marking a year-over-year decrease of 487.06%. This contributed to the annual value of $309.1 million for FY2024, which is 852.79% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Non-Current Debt stood at $297.7 million for Q3 2025, which was down 487.06% from $301.5 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Non-Current Debt peaked at $312.9 million during Q3 2024, and registered a low of $169.0 million during Q1 2021.
  • For the 5-year period, Ani Pharmaceuticals' Non-Current Debt averaged around $274.3 million, with its median value being $285.7 million (2022).
  • Its Non-Current Debt has fluctuated over the past 5 years, first plummeted by 1015.93% in 2021, then soared by 6942.75% in 2022.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Non-Current Debt stood at $286.5 million in 2021, then decreased by 0.3% to $285.7 million in 2022, then fell by 0.3% to $284.8 million in 2023, then grew by 8.53% to $309.1 million in 2024, then dropped by 3.7% to $297.7 million in 2025.
  • Its last three reported values are $297.7 million in Q3 2025, $301.5 million for Q2 2025, and $305.3 million during Q1 2025.